The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - SystemsForecastingUK
Stock and Other Ownership Interests - SystemsForecastingUK
Consulting or Advisory Role - SystemsForecastingUK
Research Funding - SystemsForecastingUK
Travel, Accommodations, Expenses - SystemsForecastingUK
Differential response rates in early-phase cancer clinical trials (EPCCT).
 
Rozana Abdul Rahman
No Relationships to Disclose
 
Neethu Billy Graham Mariam
No Relationships to Disclose
 
Hitesh Mistry
No Relationships to Disclose
 
Sreeja Aruketty
No Relationships to Disclose
 
Matt Church
No Relationships to Disclose
 
Aidi Adamson-Raieste
No Relationships to Disclose
 
Julie-Anne Scott
No Relationships to Disclose
 
Fiona Thistlethwaite
Honoraria - Bayer
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst); T-Knife; Zelluna
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Zelluna
Other Relationship - iMatch
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Janssen; OM Pharma; Roche; Seagen
Speakers' Bureau - Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; Immutep
 
Louise Carter
Consulting or Advisory Role - Athenex; Bicycle Therapeutics
Research Funding - Athenex (Inst); CellCentric (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Lilly (Inst); Sierra Oncology (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Athenex; BerGenBio; BerGenBio
 
Donna M. Graham
Honoraria - McCann Health
Consulting or Advisory Role - Clinigen Group
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Incyte (Inst); Janssen (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Natalie Cook
Honoraria - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst)